Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

110.52 +0.20 (+0.18%)
Streaming Delayed Price Updated: 11:33 AM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Jazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary Endpoint
Jazz Pharmaceuticals (NASDAQ: JAZZ) announced top-line results from the Phase 3 clinical trial investigating nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in individuals with... 
Via Benzinga
Jazz Pharma's Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity
Via Benzinga
Switzerland Removes Medical Marijuana Access Limitations As Demand Rises
The Swiss government confirmed that it will remove limitations on medical marijuana use, starting August 1st, 2022. 
Via Benzinga
This Pharmaceutical Company Is Moving Beyond CBD
The applications for cannabidiol (CBD) and cannabinoid-based therapeutics are many. Many novel treatments have been, and are continuing to be, discovered using these compounds. The industry is huge... 
Via Benzinga
Leisuretown: Diplo And Rob Dyrdek's New Cannabis Seltzers Launch In California Via Agreement With HERBL
Thomas Wesley Pentz, better known for his artistic name, Diplo, partnered with California cannabis beverage company Leisuretown, professional skateboarder Rob Dyrdek and cannabis supply chain company... 
Via Benzinga
Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate
Via Benzinga
Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma
Via Benzinga
4 Analysts Have This to Say About Jazz Pharmaceuticals
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
Upgrades 
Via Benzinga
Euro Food Agency Concerned About Health Effects Of CBD, Asks For More Research
The European Food Safety Authority (EFSA) is asking for more research on the effects of CBD on humans. 
Via Benzinga
North Carolina House Says Yes To Bill Allowing FDA-Approved THC Drugs, Will This Kill Full Medical Marijuana Legalization?
The North Carolina House passed Senate Bill 448, legalizing FDA-approved THC medications in a 92-9 vote, reported The Carolina Journal. 
Via Benzinga
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
FDA Battles Over CBD Hype Yet Again, This Time Warns Businesses Selling Illegal CBD For Food-Producing Animals
The Food and Drug Administration (FDA) sent letters to four CBD companies warning them against selling unauthorized CBD products for use in food-producing animals. Companies being warned are Haniel... 
Via Benzinga
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,... 
Via FinancialNewsMedia
Exposures COVID-19
Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating
Jazz Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level. 
Via Investor's Business Daily
Jazz Pharmaceuticals's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Jazz Pharmaceuticals (NASDAQ:JAZZ) posted Q1 earnings of $1.65 million, an increase from Q4 of 104.66%. Sales dropped to $813.72 million, a 9.26% decrease between... 
Via Benzinga
What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval?
Avadel Pharmaceuticals PLC (NASDAQ: AVDL) reported 1Q results and provided updated color on the U.S. marketing application for FT218. 
Via Benzinga
Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next?
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has completed the divestiture of Sunosi (solriamfetol) in the U.S. 
Via Benzinga
What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2022. 
Via Benzinga
Jazz Pharmaceuticals: Q1 Earnings Insights
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q1 earnings results on Wednesday, May 4, 2022 at 05:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
EXCLUSIVE: Aurora Cannabis CEO 'Absolutely Confident' Company Will Be EBITDA-Positive By Year's End
Miguel Martin, CEO of Aurora Cannabis Inc (NASDAQ: ACB), discussed growing Aurora into the leader of the international medical cannabis market at the Benzinga Cannabis Capital Conference on Wednesday. 
Via Benzinga
Axsome Therapeutics Stock Rockets As Its First FDA Approval Looks Imminent
The company agreed to the FDA's post-marketing requirements for a depression drug. 
Via Investor's Business Daily
Avicanna's Cannabinoid Drugs To Reach Brazil Via Its First 'Big Pharma' Deal
Via Benzinga
Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies
Syros Pharmaceuticals Inc (NASDAQ: SYRS)  
Via Benzinga
Expert Ratings For Jazz Pharmaceuticals
Over the past 3 months, 4 analysts have published their opinion on Jazz Pharmaceuticals (NASDAQ:JAZZ) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Raymond James reduced the price target on Intercontinental Exchange, Inc. (NYSE: ICE) from $161 to $157. Intercontinental Exchange shares rose 0.2% to $130.79 in pre-market trading. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.